Globus Medical (NYSE:GMED) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker10Welcome to Globus Medical's fourth quarter and full year 2025 earnings call. At this time, all lines will be on mute, and a question and answer session will be held after the prepared remarks. I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead.Speaker1Thank you, Dana. Thank you everyone for being with us today. Joining today's c ...

Group 1 - EnviroGold Global Limited's common shares will be delisted from the Canadian Securities Exchange (CSE) at market close on February 3, 2026 [1][2] - The issuer will continue to trade on the TSX Venture Exchange [1][2] - The stock symbol for EnviroGold Global Limited is NVRO [3]

Core Viewpoint - EnviroGold Global Limited is hosting a live investor webinar to discuss the opportunity of recovering precious and critical metals from existing above-ground assets using its proprietary NVRO Process™, which aligns with global supply-security objectives and offers improved economic and environmental outcomes [1][3]. Company Strategy and Objectives - The webinar will outline the company's strategy, path to revenue and earnings, technology buildout, strategic partnerships, and key objectives for 2026 [2]. - The presentation aims to provide a clear, non-technical understanding of EnviroGold's opportunity and long-term value creation pathway [9]. Market Context and Opportunities - Rising global demand for gold, silver, copper, and critical minerals is driven by electrification, infrastructure investment, defense requirements, and supply chain resilience [4]. - New mine development is constrained by lengthy permitting timelines, capital intensity, and environmental considerations, making tailings a significant, under-recognized source of metal supply [4][5]. NVRO Process™ and Environmental Impact - The NVRO Process™ allows mining companies to recover additional precious and critical metals from existing tailings, improving asset returns while reducing long-term environmental liabilities [6]. - This approach, termed "Metals Without Mining," enhances and complements existing mining operations [6]. Regulatory Alignment and Competitive Advantage - Governments are prioritizing secure, domestic sources of precious and critical metals, with U.S. critical minerals mandates recognizing recycling and secondary recovery as essential for supply-chain security [7]. - Recovery using the NVRO Process™ can be achieved faster and at lower costs than developing new mines, while also delivering improved environmental outcomes [8]. Webinar Focus Areas - The webinar will cover the scale of the global above-ground metals opportunity, economic and environmental advantages of tailings recovery, critical-minerals policy support, and the NVRO Process™ [10]. - It will also discuss EnviroGold's capital-light, licensing-led business model and key milestones expected in 2026 [10].

Core Viewpoint - EnviroGold Global Limited has successfully converted and retired approximately $10.2 million in debt, marking a significant milestone as it moves towards the commercialization of its proprietary NVRO Process™ [1][3]. Debt Conversion and Financial Position - The company fully converted $4,119,000 in Convertible Promissory Notes into 68,650,446 shares at $0.06 per share, with additional shares issued for interest and costs [2]. - The retirement of all convertible and promissory liabilities results in a clean balance sheet, positioning the company for future growth [3]. Insider Transactions - Two insiders converted a total of $100,000 in principal of the Notes into common shares, which is classified as a related-party transaction under MI 61-101 [3]. - The company is relying on exemptions from formal valuation and minority shareholder approval requirements due to the fair-market value of the securities issued not exceeding C$2,500,000 [3]. Corporate Matters - The company will issue 1,851,852 common shares at a deemed price of $0.135 per share as partial payment for an engagement fee to Cantor Fitzgerald Canada Corporation [4]. - An aggregate of 850,000 common shares will be issued to the estate of former director Harold Wolkin in recognition of his services [5]. Equity Awards and Incentives - The company issued conversion premiums totaling 1,271,405 shares at a deemed price of $0.15 per share in connection with the Note conversions [6]. - On November 6, 2025, the company granted 5,637,501 restricted share units (RSUs), 18,500,000 performance share units (PSUs), and 257,000 stock options to directors and officers as incentive compensation [8]. Performance Conditions - The Options are exercisable at $0.14 per share for five years and vested upon issuance, while RSUs will vest in tranches according to individual agreements [9]. - PSUs are tied to performance-based milestones, including revenue thresholds and volume-weighted average price (VWAP) targets [10]. Company Overview - EnviroGold Global Limited focuses on transforming the mining industry by recovering high-value metals from mine waste and tailings, utilizing its proprietary NVRO Process™ for efficient, low-carbon extraction [14].

Core Viewpoint - Globus Medical's acquisition of Nevro has positively impacted its financial performance, leading to a significant increase in stock value and an optimistic outlook for future earnings growth [2][3][4]. Financial Performance - Globus Medical reported third-quarter sales of $769 million, representing a 6.4% organic growth, surpassing forecasts of $735 million [4]. - Adjusted earnings per share reached $1.18, exceeding expectations of 78 cents, with a notable 42% increase year-over-year [4]. - Nevro's sales were $99 million, reflecting a modest 2% year-over-year growth, but its adjusted EBITDA margin improved to 16% from a prior loss of 1% [2][4]. Future Outlook - The company has raised its full-year sales guidance to a range of $2.86 billion to $2.9 billion, up from the previous range of $2.8 billion to $2.9 billion [6]. - Adjusted profit expectations have also increased to $3.75 to $3.85 per share, marking a 65-cent increase at the midpoint from previous guidance [6]. - Management anticipates that the Nevro division will become accretive by 2025, earlier than previously expected [3]. Market Reaction - Following the positive earnings report, Globus Medical's stock surged by 36.1%, closing at $83.89, marking an eight-month high and surpassing its 200-day moving average [3][4].

Financial Data and Key Metrics Changes - Globus Medical reported Q3 2025 sales of $769 million, a 22.9% increase year-over-year, with non-GAAP diluted earnings per share of $1.18, growing 42.6% compared to the prior year quarter [4][19][35] - Free cash flow reached a record $213.9 million for the quarter, contributing to a strong cash flow generation profile [4][33] - Adjusted EBITDA margin for the base Globus business was 35.3%, an increase of 435 basis points from the prior year quarter [5][21] Business Line Data and Key Metrics Changes - The U.S. spine business grew 9.6% as reported, continuing a trend of 32 weeks of consecutive growth [6][24] - Trauma business achieved a strong growth of 17.2%, marking the highest quarterly revenue since its inception [13][22] - Enabling technologies revenue declined 26.8% to $28 million, primarily due to lower sales of eGPS systems [8][22] Market Data and Key Metrics Changes - International spine business grew 5.6% as reported, with notable growth in EMEA and Asia-Pacific regions [11][12] - U.S. revenue during Q3 2025 was $617.6 million, growing 24.6% as reported, driven by strong performance in spine, trauma, and neuromonitoring [24][25] - Nevro contributed $99.3 million in revenue, growing 4.9% sequentially, indicating positive integration progress [15][23] Company Strategy and Development Direction - The company remains focused on partnering with surgeons to address unmet clinical needs and drive operational excellence [16] - There is a strategic shift towards flexible capital acquisition models, moving away from traditional cash sales to leasing and rental options [11][42] - The integration of Nevro is expected to enhance growth and profitability, with a focus on driving new product development and expanding the sales force [15][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the U.S. spine market and anticipates continued growth in both domestic and international markets [70] - The company expects to achieve revenue growth in the range of 13.5% to 15.1% for 2025, with non-GAAP earnings per share guidance increased to between $3.75 and $3.85 [34][35] - Management highlighted the importance of maintaining operational excellence while pursuing organic growth opportunities [72] Other Important Information - The company has been active in share repurchases, spending $40 million in Q3 2025, with a total of $256 million year-to-date [5][31] - Research and development expenses were $38.1 million, or 4.9% of sales, reflecting a decline due to synergy capture [27] - SG&A expenses included one-time litigation charges of $28.3 million, impacting the overall expense ratio [29] Q&A Session Summary Question: What is driving the strength and acceleration in U.S. Core Spine? - Management noted 32 weeks of consecutive sales growth, with broad strength across all categories, driven by competitive recruiting and new product launches [38][39] Question: What are the expectations for Nevro's margin progression? - Nevro's EBITDA margin was 16.2%, with plans to drive efficiency and growth through better product development and sales force integration [46][48] Question: How is the enabling tech business expected to perform in Q4? - Management expressed confidence in the pipeline, indicating potential for strong revenue generation despite recent slower sales [50][51] Question: What are the plans for Nevro's product portfolio? - Future developments may include expanding into peripheral nerve treatments and addressing conditions like diabetic neuropathy and Parkinson's tremors [55][56] Question: What is the strategy regarding flexible payment models? - The company is seeing an increase in requests for flexible capital acquisition models, which may affect revenue recognition timing [42][57]

Core Insights - Globus Medical, Inc. (GMED) reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, exceeding the Zacks Consensus Estimate by 13.16% and reflecting a year-over-year increase of 14.1% [1][9] - The company's revenues for the quarter reached $745.3 million, marking an 18.4% increase year over year and surpassing the Zacks Consensus Estimate by 0.49% [3][9] - GMED's gross profit rose 34.3% year over year to $496.6 million, with a gross margin expansion of 792 basis points to 66.6% [6][9] Revenue Performance - Worldwide sales increased to $745.3 million, driven by a $95 million contribution from the recently acquired Nevro [3][9] - U.S. net sales grew 20.3% year over year to $600.8 million, while international revenues rose 11% to $144.6 million [4] Product Performance - Musculoskeletal Solutions generated revenues of $710.2 million, up 19.8% year over year, while Enabling Technologies saw a decline of 4.4% to $35.2 million [5] Margin and Profitability - Adjusted operating profit was $153 million, a 65.4% increase from the previous year, with an adjusted operating margin of 20.5% [7] - SG&A expenses increased by 26.8% to $303.6 million, while research and development expenses rose 5.9% to $40 million [6] Cash Position - At the end of Q2 2025, GMED had combined cash and cash equivalents of $229.4 million, down from $461.3 million at the end of Q1 [8] - Net cash provided by operating activities was $255.2 million, compared to $106.6 million in the prior year [8] Guidance - GMED reaffirmed its full-year 2025 guidance, projecting net sales between $2.80 billion and $2.90 billion, with adjusted EPS expected in the range of $3.00 to $3.30 [10] Market Position - The company experienced strong momentum in the U.S. Spine business, achieving its highest sequential revenue growth since Q2 2022, with notable growth in the EMEA region [11] - GMED is increasing investment and output to enhance product delivery and engagement with surgeon partners [12]

Financial Data and Key Metrics Changes - Globus Medical reported Q2 sales of $745 million, with non-GAAP EPS of $0.86, reflecting growth of 18.4% and 14.1% respectively compared to the prior year quarter [14][42] - Free cash flow was $31.3 million, growing 18% despite the impact of the Nevro acquisition and higher CapEx spending [14][36] - Adjusted EBITDA margins for the base Globus business were 32.3%, growing 210 basis points over the prior year quarter [36][52] Business Line Data and Key Metrics Changes - The base business generated $651 million in revenue during Q2, growing 3.3% as reported and 4.9% day adjusted [14][46] - Nevro contributed $95 million in revenue during the quarter, with operational challenges largely subsided [15][47] - The U.S. Spine business grew 5.7% as reported or 7.4% on a day adjusted basis, driven by key procedures and consistent growth [16][17] Market Data and Key Metrics Changes - U.S. revenue during Q2 was $600.8 million, growing 20.3% as reported [49] - International revenue was $144.6 million, growing 11% as reported and 7.5% on a constant currency basis [51] - The EMEA region saw growth led by the UK, Spain, Germany, Ireland, and Italy, while the APAC region focused on Japan and Australia [21][23] Company Strategy and Development Direction - The company aims to become the preeminent musculoskeletal technology company, focusing on improving clinical outcomes and addressing unmet clinical needs [10][11] - There is a strong emphasis on integrating merged and acquired entities, accelerating product development, and maintaining financial discipline [12][13] - The strategy includes expanding the product portfolio and enhancing the sales force through competitive rep conversions [12][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position in the market and the potential for organic growth, particularly in the U.S. Spine business [12][34] - The integration of Nevro is expected to drive top-line growth while rightsizing profitability [59] - The leadership transition is viewed as an inflection point for growth, with confidence in the new CEO and CFO [88][90] Other Important Information - The company remains debt-free while generating strong free cash flow and investing in business growth [36][57] - The acquisition of Nevro was seen as a strategic opportunity, enhancing the product portfolio and addressing a broader continuum of care [30][45] - The company has launched 21 new products since the beginning of 2024, with a focus on innovation and filling gaps in the product portfolio [32][33] Q&A Session Summary Question: Progress with Nevro - Management expressed cautious optimism about the integration of Nevro, highlighting energized sales force and early benefits from cost containment activities [66][70] Question: Enabling Technology and Robots - Enabling Technologies saw a bounce back in Q2, with the pipeline remaining active and no significant loss of deals to competition [71][73] Question: Investor Communication Strategy - The company plans to enhance investor outreach and will hold an Investor Day in the future [78][79] Question: Augmented Reality Headset Launch - The launch plan for the augmented reality headset is underway, with a focus on integrating it into the Excelsius ecosystem [81][83] Question: Leadership Transition - Management reassured investors about the continuity in leadership and the depth of the leadership bench, emphasizing stability and strategic focus [87][88] Question: Nevro's Growth Strategy - The strategy for Nevro includes stability in approach, honing product development, and consistent commercial strategy to ensure long-term growth [91][93]

Summary of Conference Call for Zimmer Biomet Industry and Company Overview - The conference call involved Zimmer Biomet, a company in the orthopedic medical device industry, focusing on product launches and financial guidance for 2025 [1][2]. Key Points and Arguments Tariff Impact - Estimated overall tariff impact for 2025 is between $60 million to $80 million, primarily affecting the second half of the year [5][6]. - Key assumptions include a 10% baseline tariff globally, with specific higher tariffs on products from China and the U.S. [5][9]. - The company is taking a conservative approach regarding the Nairobi protocol, not speculating on its applicability [8][12]. - The situation regarding tariffs remains fluid, and updates will be provided in the second quarter call [6][7]. Financial Guidance and Growth Projections - The company is confident in achieving organic, constant currency revenue growth of 3% to 5% for 2025, despite a slower first quarter growth of approximately 2.3% to 2.4% [18][19]. - The second half of 2025 is expected to show stronger growth due to favorable comparisons and new product launches [19][20]. - New product introductions, referred to as the "Magnificent Seven," are anticipated to significantly impact growth in the latter half of the year [19][20]. New Product Launches - Strong momentum is noted in the hip product category, particularly with the triple taper hip stem and AI navigation products [31][32]. - The company expects robust growth in knee products in the second half of the year, particularly with Persona Osteo Tie and robotics [32][33]. - The market for cementless knees is underpenetrated, with expectations for increased adoption due to better fixation rates and surgical efficiency [35][36]. Competitive Landscape - Zimmer Biomet remains the number one company in the knee and hip markets, despite competitive pressures from companies like Smith & Nephew and J&J [42][43]. - The company is focused on maintaining its leadership position through new product innovations and strategic investments [43]. Leadership and Organizational Changes - A new head of U.S. commercial operations has been appointed, emphasizing an evolutionary approach rather than radical changes [44][46]. - The leadership team is confident in executing the 2025 plan and long-range plan (LRP) [47][48]. Acquisition Strategy - The integration of Paragon 28 is progressing well, with no talent loss and positive opportunities in the ASC environment [50][51]. - The company aims for responsible M&A to achieve a 5% WEMGARD growth rate by 2027, with a focus on organic growth as well [54][55]. Financial Performance and Margins - The company has consistently grown earnings at a rate of 5% to 9% over the past four years, with expectations to replicate this growth in 2025 [69][70]. - Gross margins are expected to remain stable despite potential headwinds from tariffs and currency fluctuations [72][73]. Stock Buybacks and Capital Deployment - The company is open to opportunistic stock buybacks, balancing this strategy with M&A opportunities [82][83]. Other Important Content - The company is focused on reallocating resources effectively to enhance growth, with a significant investment in innovation [60][66]. - The management emphasizes the importance of maintaining a strong balance sheet to support ongoing and future growth initiatives [84][85].

Core Viewpoint - Globus Medical reported a decline in net sales for Q1 2025, attributed to multiple factors including slowed technology transactions, supply chain disruptions, and fluctuations in international distributor orders, although the core U.S. spine business performed well [4][6]. Financial Performance - For Q1 2025, Globus Medical's global net sales were $598.1 million (approximately 4.3 billion RMB), a year-over-year decrease of 1.4%. On a constant currency basis, the decline was 0.8% [6]. - The GAAP net income for the quarter was $75.5 million, with a GAAP diluted earnings per share (EPS) of $0.54 and a non-GAAP diluted EPS of $0.68 [6]. - The company generated a record free cash flow of $141.2 million during the quarter and reaffirmed its full-year revenue guidance of $2.8 to $2.9 billion, while updating its non-GAAP EPS guidance to a range of $3.00 to $3.30 [6]. Mergers and Acquisitions - In February 2023, Globus Medical announced a $3.1 billion (approximately 21.1 billion RMB) acquisition of NuVasive, with NuVasive shareholders owning about 28% of the combined company post-transaction [4][7]. - The acquisition of Nevro for approximately $250 million was announced in early 2025, with a premium of 27% over Nevro's average stock price over the past 90 days [9][11]. Strategic Developments - The merger with NuVasive is expected to enhance the combined company's capabilities in the $50 billion global market for spine and orthopedic technologies, with analysts praising the integration as one of the most successful in the spine industry [7]. - The company launched 18 new products in 2024, including innovations that leverage the strengths of both companies, such as the ExcelsiusHub robotic platform integrated with Pulse neuro-monitoring technology [13]. Leadership Changes - In February 2025, the company announced that President Anthony L. Williams would leave by May 31, 2025, with CEO Dan Scavilla temporarily taking over the role to ensure operational stability during the transition [8].